Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor

a technology of factor xa inhibitor and anticoagulant therapy, which is applied in the direction of extracellular fluid disorder, antibody medical ingredients, metabolic disorders, etc., can solve the problems of insufficient therapeutic benefit, inability to combine with an antiplatelet agent at a fixed dose, and current anticoagulant therapies are not suitable for combination therapy, so as to achieve superior efficacy or safety, the effect of predicting the level of anticoagulation

Inactive Publication Date: 2008-10-16
MILLENNIUM PHARMA INC
View PDF25 Cites 46 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0009]Compound A has been shown to have predictable levels of anticoagulation as measured by pharmacodynamic assays. This is more thoroughly described in Examples 2 and 3. Thus, it is contemplated that Compound A can surprisingly and unexpectedly be used in a fixed, non-dose-titrated manner in combination with other therapeutic agents for the treatment of thrombotic disease. It is further contemplated that Compound A when provided in combination with certain other therapeutic agents shows a synergistic effect illustrated by superior efficacy or safety profile.

Problems solved by technology

However, some current anticoagulants therapies are not suitable for combination therapy.
Therefore it cannot be used as a combination with an antiplatelet agent at a fixed dose.
Further, while some anticoagulant agents and antiplatelet agents may be suitable for combination therapy, they do not provide sufficient therapeutic benefit.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor
  • Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor
  • Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of Compound A

[0209]

Step 1:

[0210]5-Methoxy-2-nitrobenzoic acid (1) (25.0 kg, 1.0 eq), 2-amino-5-chloropyridine (2) (16.3 kg, 1.0 eq), and acetonitrile (87.5 kg, 3.5 parts) were charged to a 380 L GLMS reactor. The reaction mixture was adjusted to 22° C. (19 to 25° C.) and anhydrous pyridine (30.0 kg, 3.0 eq) was added. The pump and lines were rinsed forward with acetonitrile (22.5 kg, 0.9 parts), and the reactor contents were adjusted to a temperature of 19-22° C. Phosphorous oxychloride (23.3 kg, 1.20 eq) was charged to the contents of the reactor via a metering pump, while maintaining a temperature of 25° C. (22-28° C.). The metering pump and lines were rinsed forward with acetonitrile (12.5 kg, 0.5 parts), while keeping the temperature at 25° C. (22-28° C.). The reaction mixture normally turned from a slurry to a clear solution after the addition of about ⅓ of the POCl3. At the end of the addition, it became turbid. After complete addition, the reaction mixture was agi...

example 2

Thrombin Generation Inhibition Assay

[0214]In this method, human plasma samples containing the peptide gly-pro-arg-pro (Pefabloc FG, Centerchem) as an anticlotting agent, were treated with tissue factor (Innovin, Dade Behring) to initiate the generation of thrombin. After 10 min, the reaction was stopped by addition of EGTA. A chromogenic peptide substrate (Spectrozyme TH, American Diagnostica) specific for thrombin was added to measure the activity of thrombin generated during the tissue factor treatment period. After allowing the substrate cleavage reaction to proceed for 2 min, the samples were quenched with glacial acetic acid. The plasma samples were analyzed in triplicate in a 96-well plate format. Control samples containing pooled platelet poor plasma with or without added Compound A were assayed in quadruplicate on each plate. The control samples were used to establish plate acceptance criteria. Absorbance of each sample well was measured at 405 nm.

[0215]Thrombin generation (...

example 3

Anti-Factor Xa Unit Assay

[0218]The anti-factor Xa (anti-fXa) assay was adapted from a commercial kit (Diapharma COATEST LMW Heparin) and modified to a 96-well format. A low molecular weight heparin, dalteparin, included in the kit was used to construct a standard curve according to the manufacture's instruction using pooled platelets poor plasma. All samples and standards were assayed in duplicate. The limit of quantitation was 0.05 U / mL and results below 0.05 U / mL were reported as below the limit of quantitation. The upper limit of measurement for the plate assay was 1.0 U / mL and samples with anti-factor Xa units higher than 1.0 U / mL were re-assayed after dilution. The coefficient of variation (CV) for both standards and clinical samples were 10%.

[0219]FIG. 3 shows the anti-factor Xa units generated by plasma samples from healthy volunteers who were administered multiple ascending doses of Compound A.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationsaaaaaaaaaa
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
Login to view more

Abstract

The present invention is directed to methods of using combination therapies containing [2-({4-[(dimethylamino)iminomethyl]phenyl}carbonylamino)-5-methoxyphenyl]-N-(5-chloro(2-pyridyl))carboxamide for the treatment of thrombotic disease(s) and pharmaceutical compositions thereof.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Patent Application No. 60 / 911,852, filed on Apr. 13, 2007, which is hereby incorporated by reference in its entirety.FIELD OF INVENTION[0002]The present invention relates generally to novel pharmaceutical compositions and methods for treating thrombotic diseases using a combination of a factor Xa inhibitor and other agents.BACKGROUND OF THE INVENTION[0003]This invention is particularly concerned with blood coagulation and ways in which coagulation assists in maintaining the integrity of mammalian circulation after injury, inflammation, disease, congenital defect, dysfunction or other disruption. Clot formation involves the conversion of fibrinogen to fibrin which polymerizes into a network to restore hemostasis after injury. A similar process results in occluded blood vessels in thrombotic diseases. The conversion of fibrinogen to fibrin is catalyzed by throm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395A61K31/44A61K38/12A61K31/445A61K31/4365A61K31/519A61K31/47A61K31/727A61K31/60A61P7/02
CPCA61K31/44A61K45/06A61K31/4465A61K31/4365A61K39/3955A61K38/12A61K2300/00A61P29/00A61P7/00A61P7/02A61P9/00A61P9/10A61K31/4402
Inventor SINHA, UMAHOLLENBACH, STANLEY J.ANDRE, PATRICK
Owner MILLENNIUM PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap